Applied Molecular Transport Inc. (NASDAQ:AMTI – Get Rating) was the recipient of a large increase in short interest during the month of December. As of December 30th, there was short interest totalling 1,050,000 shares, an increase of 7.7% from the December 15th total of 974,600 shares. Based on an average trading volume of 301,900 shares, the days-to-cover ratio is presently 3.5 days. Approximately 4.1% of the shares of the company are sold short.
In other Applied Molecular Transport news, Director Aaron Vandevender acquired 50,000 shares of the stock in a transaction dated Monday, November 28th. The shares were purchased at an average price of $1.00 per share, for a total transaction of $50,000.00. Following the purchase, the director now directly owns 212,659 shares of the company’s stock, valued at $212,659. The acquisition was disclosed in a filing with the SEC, which is available at this link. Insiders have sold a total of 10,499 shares of company stock valued at $11,024 in the last 90 days. 25.40% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Applied Molecular Transport
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS Group AG bought a new stake in shares of Applied Molecular Transport during the third quarter valued at approximately $1,257,000. Laurion Capital Management LP bought a new stake in shares of Applied Molecular Transport during the second quarter valued at approximately $1,401,000. Vanguard Group Inc. raised its position in shares of Applied Molecular Transport by 41.4% during the third quarter. Vanguard Group Inc. now owns 1,350,774 shares of the company’s stock valued at $1,314,000 after buying an additional 395,200 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Applied Molecular Transport by 146.7% during the first quarter. Renaissance Technologies LLC now owns 428,200 shares of the company’s stock valued at $3,220,000 after buying an additional 254,600 shares during the last quarter. Finally, BlackRock Inc. raised its position in shares of Applied Molecular Transport by 5.9% during the first quarter. BlackRock Inc. now owns 2,053,572 shares of the company’s stock valued at $15,443,000 after buying an additional 114,128 shares during the last quarter. Institutional investors own 59.47% of the company’s stock.
Applied Molecular Transport Trading Up 6.4 %
Applied Molecular Transport (NASDAQ:AMTI – Get Rating) last released its earnings results on Monday, November 7th. The company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.01. Sell-side analysts forecast that Applied Molecular Transport will post -3.32 EPS for the current year.
Analyst Ratings Changes
AMTI has been the topic of several recent research reports. SVB Leerink reiterated a “market perform” rating on shares of Applied Molecular Transport in a research note on Tuesday, December 27th. Chardan Capital initiated coverage on shares of Applied Molecular Transport in a research note on Friday, December 2nd. They issued a “buy” rating on the stock. JMP Securities cut shares of Applied Molecular Transport from a “market outperform” rating to a “market perform” rating in a research note on Friday, December 23rd. Finally, Bank of America cut shares of Applied Molecular Transport from a “buy” rating to an “underperform” rating in a research note on Thursday, January 5th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $32.50.
Applied Molecular Transport Company Profile
Applied Molecular Transport Inc, a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications.
- Get a free copy of the StockNews.com research report on Applied Molecular Transport (AMTI)
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for Applied Molecular Transport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Molecular Transport and related companies with MarketBeat.com's FREE daily email newsletter.